



(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/13 (2006.01)
C12N 15/63 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2018/028206

(22) International Filing Date:

18 April 2018 (18.04.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/US2017/028206

18 April 2017 (18.04.2017) US

(71) Applicant: **R-PHARM OVERSEAS, INC.** [US/US];
12526 High Bluff Dr. Ste 300, San Diego, CA 92130 (US).

(72) Inventors: **LAVROVSKY, Yan**; 1969 Zapo Street, Del
Mar, CA 92014 (US). **XU, Ting**; 67 Wayne Road, Need-
ham, MA 02492 (US). **BARBASHOV, Sergei**; 31105
Quail Meadows, Irvine, CA 902603 (US). **REPIK, Alex-
ey**; 3 Oseniy Boulevard, Apt. 106, Moscow, 121609
(RU). **SAMSONOV, Mikhail**; 74-6-77 Leningradsky
Prospect, Moscow, 125313 (RU). **IGNATIEV, Vasily**;
13 Skolkovskoye Shosse, Apt. 212, Moscow, 121353

(RU). **ARCHUADZE, Shorena**; 19/2 Institutskaya Street,
Apt.34, Mitishi, Moscow, 141002 (RU).

(74) Agent: **KORKHIN, Yakov, M.**; SciTech Legal PC, PO
Box 15696, Boston, MA 02215 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-PD-L1 ANTIBODY AND USE THEREOF




Figure 17

(57) Abstract: Disclosed are fully human anti-PD-L1 antibodies and their corresponding applications. Fully human antibodies are capable of specifically binding to human PD-L1. Antibodies were obtained by employing a yeast display library-based screening technique and also by affinity maturation to further improve their affinity for PD-L1. The fully human anti-PD-L1 antibodies disclosed show good specificity, affinity and stability. They are capable of enhancing T cell activity by binding to activated T cells, while significantly inhibiting tumor growth. Disclosed fully human anti-PD-L1 antibodies can be used in the diagnosis and treatment of PD-L1-related cancers and other associated diseases.

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))